These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2481 related articles for article (PubMed ID: 29455639)
1. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
2. Bruton Tyrosine Kinase Inhibitors: Present and Future. Burger JA Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119 [TBL] [Abstract][Full Text] [Related]
3. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Wang Y; Zhang LL; Champlin RE; Wang ML Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675 [TBL] [Abstract][Full Text] [Related]
4. VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects. Härzschel A; Zucchetto A; Gattei V; Hartmann TN Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210016 [TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Good L; Benner B; Carson WE Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636 [TBL] [Abstract][Full Text] [Related]
6. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
7. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Smith CIE; Burger JA Front Immunol; 2021; 12():689472. PubMed ID: 34177947 [TBL] [Abstract][Full Text] [Related]
8. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. da Cunha-Bang C; Niemann CU Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220 [TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. Ponader S; Burger JA J Clin Oncol; 2014 Jun; 32(17):1830-9. PubMed ID: 24778403 [TBL] [Abstract][Full Text] [Related]
10. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies. Lucas F; Woyach JA Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175 [TBL] [Abstract][Full Text] [Related]
11. New roles for B cell receptor associated kinases: when the B cell is not the target. Nguyen PH; Niesen E; Hallek M Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840 [TBL] [Abstract][Full Text] [Related]
12. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. Maddocks K; Jones JA Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703 [TBL] [Abstract][Full Text] [Related]
13. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695 [TBL] [Abstract][Full Text] [Related]
18. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). Feng Y; Duan W; Cu X; Liang C; Xin M Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232 [TBL] [Abstract][Full Text] [Related]
19. The role of Bruton's tyrosine kinase in the immune system and disease. McDonald C; Xanthopoulos C; Kostareli E Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359 [TBL] [Abstract][Full Text] [Related]
20. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. Puri KD; Di Paolo JA; Gold MR Int Rev Immunol; 2013 Aug; 32(4):397-427. PubMed ID: 23886342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]